Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
For the sixth year in a row, Dr. Reddy's has been recognized as the only Indian pharmaceutical company in the Bloomberg Gender-Equality Index (GEI) 2023. The index features 484 companies from 11 different sectors, spanning 45 countries, and a total market capitalization of USD 16 trillion. The GEI evaluates gender equality through internal company statistics, employee policies, external community support, and gender-sensitive product offerings. It uses a comprehensive reporting framework with over 70 metrics, which are divided into five main categories:
- Leadership and talent pipeline
- Equal pay and gender pay parity
- Inclusive culture
- Anti-sexual harassment policies
- External brand
Furthering its accolades, Dr. Reddy's has earned a place in the Sustainability Yearbook 2023 for the third year in a row, based on the results of the 2022 S&P Global Corporate Sustainability Assessment (CSA). The CSA evaluates 61 industries, comprising over 7,800 companies, with 140,000 documents analyzed and 14 million data points considered. To be listed in the Yearbook, companies must rank within the top 15% of their industry and attain an S&P Global Sustainability Score within 30% of the highest-performing company in their sector.
Additionally, because of the CSA and other screening processes, Dr. Reddy's has again been named among the world's leading companies for sustainability for the seventh year in a row on the Dow Jones Sustainability Index (DJSI) in the Emerging Markets category. This recognition highlights the company's ability to create value and mitigate risks through its Environmental, Social, and Governance (ESG) potential. The DJSI Emerging Markets Index showcases the top 10% of the 800 largest companies across 20 emerging markets based on careful long-term economic, environmental, and social considerations.